- Home
- PGEN vs CMPS Comparison
PGEN vs CMPS Comparison
Compare PGEN & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PGEN | CMPS |
|---|---|---|
| Founded | 1998 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PGEN | CMPS |
|---|---|---|
| Price | $7.13 | $13.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $8.33 | ★ $25.38 |
| AVG Volume (30 Days) | ★ 6.0M | 2.6M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $230,981,000.00 | N/A |
| Revenue This Year | $1,115.92 | N/A |
| Revenue Next Year | $81.04 | N/A |
| P/E Ratio | $248.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.99 | $4.40 |
| 52 Week High | $7.49 | $15.40 |
Technical Indicators
Market Signals| Indicator | PGEN | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 62.70 | 54.45 |
| Support Level | $3.96 | $13.06 |
| Resistance Level | $7.32 | $14.84 |
| Average True Range (ATR) | 0.44 | 0.74 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 75.70 | 66.08 |
Price Performance
Historical ComparisonAbout PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.